

Global Vaccine Market Outlook 2020

https://marketpublishers.com/r/GC6E12CC2A3EN.html

Date: April 2014

Pages: 135

Price: US\$ 1,500.00 (Single User License)

ID: GC6E12CC2A3EN

Abstracts

The pharmaceutical segment has faced diminishing prospects because of declining research and development productivity, stringent regulatory activities and generic competition for off patent products. On the contrary, vaccine segment has developed as highly profitable because of advancements in genomics and manufacturing technologies as well as increasing demand from emerging economies.

Meanwhile, continuous efforts have been put in by the biopharmaceutical companies to create tremendous opportunities for leading players to tap this market. Besides, vaccines have high entry barrier for generic players and potential to generate blockbuster sales, which thereby allure the market players.

The report, "Global Vaccine Market Outlook 2020" provides an extensive research and in-depth analysis of the current status and future outlook of the global vaccine market. The market, which stood at US\$ 30.5 Billion in 2013, is expected to grow at a CAGR of around 12% during 2013-2020.

In our report, we have segmented the global vaccine market based on 16 therapeutic categories, and market for each has been forecasted. For each therapeutic segment, marketed product portfolio, pipeline products along with recent developments have been analyzed. Followed by this, important geographies have been highlighted along with their current and future markets outlook till 2020. The report also covers advanced stage pipeline analysis of key players, which list down the vaccines already in Phase III trials. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth.

In the end, various key players have been enlisted. Our team has analyzed each company's strengths and weaknesses along with its vaccine portfolio and pipeline that



will help the reader to better position his company vis-à-vis competition.



Contents

- 1. ANALYST VIEW
- 2. RESEARCH METHODOLOGY
- 3. GLOBAL VACCINE MARKET OUTLOOK TO 2020
- 4. MAJOR VACCINES: CURRENT AND FUTURE MARKET ANALYSIS
- 4.1 Pneumococcal
- 4.2 Influenza
- 4.3 Cancer
- 4.4 Polio
- 4.5 Varicella
- 4.6 Rotavirus
- 4.7 Meningococcal
- 4.8 DTP
- 4.9 Hepatitis
- 4.10 Measles, Mumps, and Rubella (MMR)
- 4.11 Japanese Encephalitis
- 4.12 Tuberculosis
- 4.13 Malaria
- 4.14 Rabies
- 4.15 Typhoid
- 4.16 HIV

5. KEY GEOGRAPHICAL MARKETS

- 5.1 US
- 5.2 Europe
- 5.3 Japan
- 5.4 China
- 5.5 India
- 5.6 Brazil

6. PIPELINE ANALYSIS

7. COMPETITIVE LANDSCAPE



7.1 GSK

- 7.1.1 Business Overview
- 7.1.2 Vaccine Portfolio & Pipeline
- 7.1.3 Strengths and Weaknesses
- 7.2 Sanofi-Pasteur
 - 7.2.1 Business Overview
 - 7.2.2 Vaccine Portfolio & Pipeline
 - 7.2.3 Strengths and Weaknesses
- 7.3 Pfizer
 - 7.3.1 Business Overview
 - 7.3.2 Vaccine Portfolio & Pipeline
 - 7.3.3 Strengths and Weaknesses
- 7.4 Merck
 - 7.4.1 Business Overview
 - 7.4.2 Vaccine Portfolio & Pipeline
 - 7.4.3 Strengths and Weaknesses
- 7.5 Novartis
 - 7.5.1 Business Overview
 - 7.5.2 Vaccine Portfolio & Pipeline
 - 7.5.3 Strengths and Weaknesses
- 7.6 Emergent Biosolutions
 - 7.6.1 Business Overview
 - 7.6.2 Vaccine Portfolio & Pipeline
 - 7.6.3 Strengths and Weaknesses
- 7.7 AstraZeneca Plc.
 - 7.7.1 Business Overview
 - 7.7.2 Vaccine Portfolio & Pipeline
 - 7.7.3 Strengths and Weaknesses
- 7.8 Baxter International Inc.
 - 7.8.1 Business Overview
 - 7.8.2 Vaccine Portfolio & Pipeline
 - 7.8.3 Strengths and Weaknesses
- 7.9 BioCSL (CSL Biotherapies)
 - 7.9.1 Business Overview
 - 7.9.2 Vaccine Portfolio & Pipeline
 - 7.9.3 Strengths and Weaknesses
- 7.10 Dendreon Corporation
- 7.10.1 Business Overview



- 7.10.2 Vaccine Portfolio & Pipeline
- 7.10.3 Strengths and Weaknesses
- 7.11 Takeda Pharmaceutical Company Limited
 - 7.11.1 Business Overview
 - 7.11.2 Vaccine Portfolio & Pipeline
 - 7.11.3 Strengths and Weaknesses
- 7.12 Crucell
 - 7.12.1 Business Overview
 - 7.12.2 Vaccine Portfolio & Pipeline
 - 7.12.3 Strengths and Weaknesses



List Of Figures

LIST OF FIGURES:

- Figure 3-1: Global Vaccine Market (Billion US\$), 2013-2020
- Figure 4-1: Global Causes of Deaths in Children (less 5 Years) among Low-income
- Countries (%), 2011
- Figure 4-2: Global Pneumococcal Vaccine Market (Billion US\$), 2013-2020
- Figure 4-3: Global Influenza Vaccine Market (Billion US\$), 2013-2020
- Figure 4-4: Global Cancer Vaccine Market (Billion US\$), 2013-2020
- Figure 4-5: Global Polio Vaccine Market (Billion US\$), 2013-2020
- Figure 4-6: Global Varicella Vaccine Market (Billion US\$), 2013-2020
- Figure 4-7: Global Rotavirus Vaccine Market (Billion US\$), 2013-2020
- Figure 4-8: Global Meningococcal Vaccine Market (Billion US\$), 2013-2020
- Figure 4-9: Global Number of Diphtheria Incidences by Region (2009 & 2010)
- Figure 4-10: Global Number of nTetanus Incidences by Region (2009 & 2010)
- Figure 4-11: Global Number of tTetanus Incidences by Region (2009 & 2010)
- Figure 4-12: Global Number of Pertussis Incidences by Region (2009 & 2010)
- Figure 4-13: Global DTP Vaccine Market (Billion US\$), 2013-2020
- Figure 4-14: Global Hepatitis Vaccine Market (Billion US\$), 2013-2020
- Figure 4-15: Global Number of Measles Incidences by Region (2009 & 2010)
- Figure 4-16: Global Number of Mumps Incidences by Region ('000), 2009 & 2010
- Figure 4-17: Global Number of Rubella Incidences by Region (2009 & 2010)
- Figure 4-18: Global MMR Vaccine Market (Million US\$), 2013-2020
- Figure 4-19: Global Japanese Encephalitis Market (Million US\$), 2013-2020
- Figure 4-20: Global Sources for Funding in HIV Vaccine R&D (%), 2011
- Figure 5-1: Global Vaccine Market by Region (%), 2013
- Figure 5-2: Global Vaccine Market by Region (%), 2020
- Figure 5-3: US Vaccine Market (Billion US\$), 2013-2020
- Figure 5-4: Europe Vaccine Market (Billion US\$), 2013-2020
- Figure 5-5: Japan Vaccine Market (Billion US\$), 2013-2020
- Figure 5-6: China Vaccine Market (Billion US\$), 2013-2020
- Figure 5-7: India Share of Domestic Consumption and Exports in Vaccine Market (2013)
- Figure 5-8: India Vaccine Market (Billion US\$), 2013-2020
- Figure 5-9: Brazil Vaccine Market (Billion US\$), 2013-2020
- Figure 7-1: Global Share of Key Players in Vaccine Market (2013)
- Figure 7-2: GSK Revenue Breakup by Business Segment (%), 2013
- Figure 7-3: GSK Vaccine Revenue Breakup by Product (%), 2013



- Figure 7-4: Sanofi-Pasteur Revenue Breakup by Business Segment (%), 2013
- Figure 7-5: Sanofi-Pasteur Vaccine Revenue Breakup by Product (%), 2013
- Figure 7-6: Pfizer Revenue Breakup by Business Segment (%), 2013
- Figure 7-7: Pfizer Revenue Breakup by Biopharmaceuticals (%), 2013
- Figure 7-8: Merck Revenue Breakup by Business Segment (%), 2013
- Figure 7-9: Merck Pharmaceutical Division Revenue by Segment (%), 2013
- Figure 7-10: Novartis Revenue Breakup by Business Segment (%), 2013
- Figure 7-11: AstraZeneca Revenue Breakup by Therapy Area (%), 2013
- Figure 7-12: Baxter International Revenue Breakup by Business Segment (%), 2013
- Figure 7-13: BioCSL Revenue Breakup by Business Segment (%), 2013
- Figure 7-14: Takeda Pharmaceutical Revenue Breakup by Business Segment (%), 2013
- Figure 7-15: Crucell Revenue Breakup by Vaccine Type (%), 2010



List Of Tables

LIST OF TABLES:

- Table 4-1: Pneumococcal Vaccine Market Key Players and Vaccines
- Table 4-2: Key Pneumococcal Vaccines in Pipeline
- Table 4-3: Influenza Vaccine Market Key Players and Vaccines
- Table 4-4: Key Influenza Vaccines in Pipeline
- Table 4-5: Global Cancer Statistics in More Developed and Less Developed Regions (2008)
- Table 4-6: Cancer Vaccine Market Key Players and Vaccines
- Table 4-7: Key Cancer Vaccines in Pipeline
- Table 4-8: Polio Vaccine Market Key Players and Vaccines
- Table 4-9: Key Polio Vaccines in Pipeline
- Table 4-10: Varicella Vaccine Market Key Players and Vaccines
- Table 4-11: Rotavirus Vaccine Market Key Players and Vaccines
- Table 4-12: Key Rotavirus Vaccines in Pipeline
- Table 4-13: Meningococcal Vaccine Market Key Players and Vaccines
- Table 4-14: Key Meningococcal Vaccines in Pipeline
- Table 4-15: DTP Vaccine Market Key Players and Vaccines
- Table 4-16: Key DTP Vaccines in Pipeline
- Table 4-17: Hepatitis Vaccine Market Key Players and Vaccines
- Table 4-18: Key Hepatitis Vaccines in Pipeline
- Table 4-19: MMR Vaccine Market Key Players and Vaccines
- Table 4-20: Key MMR Vaccines in Pipeline
- Table 4-21: Japanese Encephalitis Vaccine Market Key Players and Vaccines
- Table 4-22: Key Japanese Encephalitis Vaccines in Pipeline
- Table 4-23: Tuberculosis Vaccine Market Key Players and Vaccines
- Table 4-24: Key Tuberculosis Vaccines in Pipeline
- Table 4-25: Key Malaria Vaccines in Pipeline
- Table 4-26: Rabies Vaccine Market Key Players and Vaccines
- Table 4-27: Key Rabies Vaccines in Pipeline
- Table 4-28: Typhoid Vaccine Market Key Players and Vaccines
- Table 4-29: Key Typhoid Vaccines in Pipeline
- Table 4-30: Global Number of HIV/AIDS Patients by Region (2009)
- Table 4-31: Key HIV Vaccines in Pipeline
- Table 5-1: China Vaccine Classification
- Table 6-1: Vaccine Pipeline Analysis
- Table 7-1: GSK Vaccines Portfolio



- Table 7-2: GSK Vaccines in Pipeline
- Table 7-3: GSK Strengths and Weaknesses
- Table 7-4: Sanofi-Pasteur Vaccines Portfolio
- Table 7-5: Sanofi-Pasteur Vaccines in Pipeline
- Table 7-6: Sanofi-Pasteur Strengths and Weaknesses
- Table 7-7: Pfizer Vaccines Portfolio
- Table 7-8: Pfizer Vaccines in Pipeline
- Table 7-9: Pfizer Strengths and Weaknesses
- Table 7-10: Merck Vaccines Portfolio
- Table 7-11: Merck Vaccines in Pipeline
- Table 7-12: Merck Strengths and Weaknesses
- Table 7-13: Novartis Vaccines Portfolio
- Table 7-14: Novartis Vaccines in Pipeline
- Table 7-15: Novartis Strengths and Weaknesses
- Table 7-16: Emergent Biosolutions Vaccines Portfolio
- Table 7-17: Emergent Biosolutions Vaccines in Pipeline
- Table 7-18: Emergent Biosolutions Strengths and Weaknesses
- Table 7-19: AstraZeneca Vaccines Portfolio
- Table 7-20: AstraZeneca Vaccines in Pipeline
- Table 7-21: AstraZeneca Strengths and Weaknesses
- Table 7-22: Baxter International Vaccines Portfolio
- Table 7-23: Baxter International Vaccines in Pipeline
- Table 7-24: Baxter International Strengths and Weaknesses
- Table 7-25: BioCSL Vaccines Portfolio
- Table 7-26: BioCSL Strengths and Weaknesses
- Table 7-27: Dendreon Corporation Vaccines Portfolio
- Table 7-28: Dendreon Corporation Vaccines in Pipeline
- Table 7-29: Dendreon Corporation Strengths and Weaknesses
- Table 7-30: Takeda Pharmaceutical Vaccines Portfolio
- Table 7-31: Takeda Pharmaceutical Vaccines in Pipeline
- Table 7-32: Takeda Pharmaceutical Strengths and Weaknesses
- Table 7-33: Crucell Vaccines Portfolio
- Table 7-34: Crucell Vaccines in Pipeline
- Table 7-35: Crucell Strengths and Weaknesses



I would like to order

Product name: Global Vaccine Market Outlook 2020

Product link: https://marketpublishers.com/r/GC6E12CC2A3EN.html

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GC6E12CC2A3EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970